.Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA15_DexmethylphenidateAndSerdexmethy.DexmethylphenidateAndSerdexmethy .Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA15_DexmethylphenidateAndSerdexmethy.DexmethylphenidateAndSerdexmethy| name: | DexmethylphenidateAndSerdexmethylphenidate |
| ATC code: | N06BA15 | route: | oral |
| n-compartments | 2 |
Dexmethylphenidate is the d-threo-enantiomer of methylphenidate, a central nervous system stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Serdexmethylphenidate is a prodrug of dexmethylphenidate designed for extended-release formulations. The combination is approved and marketed for the treatment of ADHD.
Pharmacokinetic parameters estimated for healthy adults based on known pharmacokinetics of dexmethylphenidate and serdexmethylphenidate (CNS stimulant, oral administration). No published non-compartmental or compartmental population PK modeling reports currently available; estimates extrapolated from clinical pharmacology data.